JP2017508764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508764A5 JP2017508764A5 JP2016558141A JP2016558141A JP2017508764A5 JP 2017508764 A5 JP2017508764 A5 JP 2017508764A5 JP 2016558141 A JP2016558141 A JP 2016558141A JP 2016558141 A JP2016558141 A JP 2016558141A JP 2017508764 A5 JP2017508764 A5 JP 2017508764A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- liquid carrier
- macrogol
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 diethyl glycol Chemical compound 0.000 claims description 12
- 229960003511 macrogol Drugs 0.000 claims description 12
- 229920002675 Polyoxyl Polymers 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 claims description 3
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 2
- MLHOXUWWKVQEJB-UHFFFAOYSA-N 1-acetyloxypropan-2-yl acetate Chemical compound CC(=O)OC(C)COC(C)=O MLHOXUWWKVQEJB-UHFFFAOYSA-N 0.000 claims description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-M 2-hydroxystearate Chemical compound CCCCCCCCCCCCCCCCC(O)C([O-])=O KIHBGTRZFAVZRV-UHFFFAOYSA-M 0.000 claims description 2
- 229940113118 Carrageenan Drugs 0.000 claims description 2
- 229960001777 Castor Oil Drugs 0.000 claims description 2
- 229950009789 Cetomacrogol 1000 Drugs 0.000 claims description 2
- 229940099371 DIACETYLATED MONOGLYCERIDES Drugs 0.000 claims description 2
- 229940096516 Dextrates Drugs 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 102000009338 Gastric Mucins Human genes 0.000 claims description 2
- 108010009066 Gastric Mucins Proteins 0.000 claims description 2
- 229940074045 Glyceryl Distearate Drugs 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229950005770 Hyprolose Drugs 0.000 claims description 2
- 229920002884 Laureth 4 Polymers 0.000 claims description 2
- 229950006462 Lauromacrogol 400 Drugs 0.000 claims description 2
- 229920001363 Polidocanol Polymers 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002669 Polyoxyl 20 Cetostearyl Ether Polymers 0.000 claims description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 2
- 229940068965 Polysorbates Drugs 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229940116423 Propylene glycol diacetate Drugs 0.000 claims description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N Tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- 229940061515 laureth-4 Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229920000847 nonoxynol Polymers 0.000 claims description 2
- 229920002113 octoxynol Polymers 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 150000003445 sucroses Chemical class 0.000 claims description 2
- 229920001664 tyloxapol Polymers 0.000 claims description 2
- 229960004224 tyloxapol Drugs 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- 239000000969 carrier Substances 0.000 claims 11
- 239000007788 liquid Substances 0.000 claims 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 8
- 229960002639 Sildenafil citrate Drugs 0.000 claims 4
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 claims 1
- 229940066429 Octoxynol Drugs 0.000 claims 1
- 229960000502 Poloxamer Drugs 0.000 claims 1
- 239000000305 astragalus gummifer gum Substances 0.000 claims 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium;2-hydroxyacetate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 claims 1
- 229940071117 starch glycolate Drugs 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
Description
既知の安定化剤としては、これに限定されないが：ジアセチル化モノグリセリド類、ジエチルグリコールモノパルミトステアレート、グリセリルベヘネート、グリセリルジステアレート、グリセリルモノリノレエート、グリセリルモノオレエート、グリセリルモノステアレート、自己乳化型グリセリルモノステアレート、マクロゴールセトステアリルエーテル類、セトマクロゴール１０００、９ポリオキシル２０セトステアリルエーテル、マクロゴール１５ヒドロキシステアレート、マクロゴールラウリルエーテル類、ラウレス４、ラウロマクロゴール４００、マクロゴールモノメチルエーテル類、マクロゴールオレイルエーテル類、ポリオキシル１０オレイルエーテル、マクロゴールステアレート類、ポリオキシル４０ステアレート類、メンフェゴール、モノ＆ジグリセリド類、ノノキシノール類、オクトキシノール類、ポロキサマー類、ポリオキシルヒマシ油、ポリオキシル水素化ヒマシ油、ポリソルベート類、プロピレングリコールジアセテート、プロピレングリコールラウレエート類（laureates）、プロピレングリコールジラウレート、プロピレングリコールモノラウレエート類（laureates）、プロピレングリコールモノパルミトステアレート、キラヤ、ソルビタンエステル類、ショ糖エステル類、チロキサポール、カラゲナン、セルロース、セラトニア、デキストレート類、エチルセルロース、胃ムチン、ヒプロロース(hyprolose)、ヒプロメロース、ヒプロメロースフタレート、メチルセルロース、ポリエチレンオキシド、ポリビニルアセテート、ポリビニルアルコール、シリカ類、デンプングリコール酸ナトリウム、トラガカント、キサンタンガムが挙げられる。
Claims (15)
- （ａ）水及び少なくとも２０％のエタノールを含む液体担体；及び
（ｂ）少なくとも７ｍｇ／ｍｌの濃度で前記液体担体中に溶解したシルデナフィルクエン酸塩
を含む医薬組成物。 - （ａ）水、エタノール、及び0.0075%〜20%のアセトンを含む液体担体；及び
（ｂ）少なくとも１０ｍｇ／ｍｌの濃度で前記液体担体中に溶解したシルデナフィルクエン酸塩
を含む医薬組成物。 - 前記液体担体中に溶解したシルデナフィルクエン酸塩の前記濃度が少なくとも１２．５ｍｇ／ｍｌである、請求項１又は２記載の医薬組成物。
- 前記液体担体中に溶解したシルデナフィルクエン酸塩の前記濃度が少なくとも２０ｍｇ／ｍｌである、請求項３記載の医薬組成物。
- 前記液体担体が、水と少なくとも２０％のエタノールから本質的に成る請求項１記載の医薬組成物。
- 少なくとも３５％のエタノールを含む、請求項１又は２記載の医薬組成物。
- 少なくとも５０％のエタノールを含む、請求項６記載の医薬組成物。
- 少なくとも６０％のエタノールを含む、請求項１又は２記載の医薬組成物。
- 少なくとも２４時間安定である請求項１又は２記載の医薬組成物。
- 前記液体担体のｐＨが4.4以上である、請求項１又は２記載の医薬組成物。
- 前記液体担体は、少なくとも2.5%のアセトンを含む、請求項２記載の医薬組成物。
- 前記液体担体は、少なくとも5%のアセトンを含む、請求項１１記載の医薬組成物。
- 前記液体担体は、少なくとも１０％のアセトンを含む、請求項１１記載の医薬組成物。
- 安定化剤をさらに含む、請求項２記載の医薬組成物。
- 前記安定化剤が、ジアセチル化モノグリセリド類、ジエチルグリコールモノパルミトステアレート、グリセリルベヘネート、グリセリルジステアレート、グリセリルモノリノレエート、グリセリルモノオレエート、グリセリルモノステアレート、自己乳化型グリセリルモノステアレート、マクロゴールセトステアリルエーテル類、セトマクロゴール１０００、９ポリオキシル２０セトステアリルエーテル、マクロゴール１５ヒドロキシステアレート、マクロゴールラウリルエーテル類、ラウレス４、ラウロマクロゴール４００、マクロゴールモノメチルエーテル類、マクロゴールオレイルエーテル類、ポリオキシル１０オレイルエーテル、マクロゴールステアレート類、ポリオキシル４０ステアレート類、メンフェゴール、モノ＆ジグリセリド類、ノノキシノール類、オクトキシノール類、ポロキサマー類、ポリオキシルヒマシ油、ポリオキシル水素化ヒマシ油、ポリソルベート類、プロピレングリコールジアセテート、プロピレングリコールラウレエート類（laureates）、プロピレングリコールジラウレート、プロピレングリコールモノラウレエート類（laureates）、プロピレングリコールモノパルミトステアレート、キラヤ、ソルビタンエステル類、ショ糖エステル類、チロキサポール、カラゲナン、セルロース、セラトニア、デキストレート類、エチルセルロース、胃ムチン、ヒプロロース(hyprolose)、ヒプロメロース、ヒプロメロースフタレート、メチルセルロース、ポリエチレンオキシド、ポリビニルアセテート、ポリビニルアルコール、シリカ類、デンプングリコール酸ナトリウム、トラガカント、及びキサンタンガムから成る群より選ばれる、請求項１４記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955299P | 2014-03-19 | 2014-03-19 | |
| US61/955,299 | 2014-03-19 | ||
| PCT/IB2015/052014 WO2015140748A2 (en) | 2014-03-19 | 2015-03-19 | Sildenafil solutions and methods of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508764A JP2017508764A (ja) | 2017-03-30 |
| JP2017508764A5 true JP2017508764A5 (ja) | 2018-05-10 |
| JP6744821B2 JP6744821B2 (ja) | 2020-08-19 |
Family
ID=54145440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558141A Expired - Fee Related JP6744821B2 (ja) | 2014-03-19 | 2015-03-19 | シルデナフィル液剤並びにその製造方法及び使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968609B2 (ja) |
| EP (2) | EP3372083A1 (ja) |
| JP (1) | JP6744821B2 (ja) |
| KR (1) | KR20160137584A (ja) |
| CN (1) | CN106132204B (ja) |
| AU (2) | AU2015233006B2 (ja) |
| CA (1) | CA2942628C (ja) |
| CL (1) | CL2016002318A1 (ja) |
| CY (1) | CY1120187T1 (ja) |
| DK (1) | DK3119201T3 (ja) |
| EA (1) | EA032819B1 (ja) |
| ES (1) | ES2668915T3 (ja) |
| HR (1) | HRP20180773T1 (ja) |
| HU (1) | HUE038431T2 (ja) |
| IL (1) | IL247840B (ja) |
| LT (1) | LT3119201T (ja) |
| MX (1) | MX371276B (ja) |
| NO (1) | NO2723977T3 (ja) |
| PL (1) | PL3119201T3 (ja) |
| PT (1) | PT3119201T (ja) |
| RS (1) | RS57206B1 (ja) |
| SG (2) | SG11201607507VA (ja) |
| SI (1) | SI3119201T1 (ja) |
| WO (1) | WO2015140748A2 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2723977T3 (ja) | 2014-03-19 | 2018-03-10 | ||
| JP6902372B2 (ja) * | 2017-02-28 | 2021-07-14 | ヱスビー食品株式会社 | 苦味抑制用組成物 |
| US11464778B2 (en) * | 2017-12-26 | 2022-10-11 | Liqmeds Worldwide Limited | Liquid oral formulations for sildenafil |
| US20220193081A1 (en) * | 2019-04-18 | 2022-06-23 | Ellamed Ip & Services Pte. Ltd. | Liquid sildenafil citrate compositions |
| WO2021096871A2 (en) * | 2019-11-12 | 2021-05-20 | American Regent, Inc. | Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhages |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785984A (en) * | 1993-02-05 | 1998-07-28 | Kao Corporation | Taste-modifying method and bitterness-decreasing method |
| EP0635218B1 (en) * | 1993-02-05 | 2000-10-25 | Kao Corporation | Taste modifying method and bitter taste reducing method |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| CA2391968A1 (en) * | 1999-11-18 | 2001-05-25 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
| EP1255566A2 (en) | 2000-02-04 | 2002-11-13 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| EP1301186A1 (en) | 2000-07-19 | 2003-04-16 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| US20070065394A1 (en) | 2003-11-17 | 2007-03-22 | Pinney Virginia R | Compositions effective in altering the perception of malodor |
| ATE387203T1 (de) | 2004-01-05 | 2008-03-15 | Teva Pharma | Prozesse zur herstellung von sildenafil-base und zitratsalz |
| CN1925860A (zh) * | 2004-01-05 | 2007-03-07 | 特瓦制药工业有限公司 | 制备西地那非碱及其柠檬酸盐的方法 |
| US7727565B2 (en) | 2004-08-25 | 2010-06-01 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
| JP4972081B2 (ja) | 2005-03-14 | 2012-07-11 | ワイス・エルエルシー | チゲサイクリン組成物および調製方法 |
| US7556487B2 (en) | 2006-03-29 | 2009-07-07 | Intergum Gida Sinayi ve Ticaret A.S. | Apparatus for making center-filled chewing gum pieces |
| FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
| EP2008530B1 (de) | 2007-06-19 | 2011-01-19 | Symrise AG | Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck |
| EP2072044A1 (en) * | 2007-12-19 | 2009-06-24 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising a liquid or flowable core composition |
| WO2009125415A1 (en) | 2008-04-07 | 2009-10-15 | Hetero Research Foundation | Amorphous form of sildenafil citrate |
| FR2939321B1 (fr) | 2008-12-05 | 2011-08-26 | Philippe Perovitch | Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| DE102010049708A1 (de) * | 2010-10-28 | 2012-05-03 | Hexal Ag | Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe |
| EP2787967B1 (en) * | 2011-12-05 | 2018-10-31 | Suda Limited | Oral spray formulations and methods for administration of sildenafil |
| GB2497933B (en) | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
| AU2013262320B2 (en) * | 2012-05-16 | 2018-02-22 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
| US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| NO2723977T3 (ja) | 2014-03-19 | 2018-03-10 |
-
2012
- 2012-04-16 NO NO12802846A patent/NO2723977T3/no unknown
-
2015
- 2015-03-19 AU AU2015233006A patent/AU2015233006B2/en not_active Ceased
- 2015-03-19 EP EP18161634.3A patent/EP3372083A1/en not_active Withdrawn
- 2015-03-19 LT LTEP15764710.8T patent/LT3119201T/lt unknown
- 2015-03-19 SG SG11201607507VA patent/SG11201607507VA/en unknown
- 2015-03-19 MX MX2016012154A patent/MX371276B/es active IP Right Grant
- 2015-03-19 KR KR1020167029017A patent/KR20160137584A/ko not_active Application Discontinuation
- 2015-03-19 RS RS20180533A patent/RS57206B1/sr unknown
- 2015-03-19 SG SG10201808038TA patent/SG10201808038TA/en unknown
- 2015-03-19 EA EA201691871A patent/EA032819B1/ru unknown
- 2015-03-19 JP JP2016558141A patent/JP6744821B2/ja not_active Expired - Fee Related
- 2015-03-19 ES ES15764710.8T patent/ES2668915T3/es active Active
- 2015-03-19 PL PL15764710T patent/PL3119201T3/pl unknown
- 2015-03-19 WO PCT/IB2015/052014 patent/WO2015140748A2/en active Application Filing
- 2015-03-19 CN CN201580013951.5A patent/CN106132204B/zh not_active Expired - Fee Related
- 2015-03-19 EP EP15764710.8A patent/EP3119201B1/en active Active
- 2015-03-19 DK DK15764710.8T patent/DK3119201T3/en active
- 2015-03-19 HU HUE15764710A patent/HUE038431T2/hu unknown
- 2015-03-19 SI SI201530249T patent/SI3119201T1/en unknown
- 2015-03-19 CA CA2942628A patent/CA2942628C/en active Active
- 2015-03-19 PT PT157647108T patent/PT3119201T/pt unknown
-
2016
- 2016-09-14 CL CL2016002318A patent/CL2016002318A1/es unknown
- 2016-09-15 IL IL247840A patent/IL247840B/en active IP Right Grant
- 2016-09-15 US US15/265,897 patent/US9968609B2/en not_active Expired - Fee Related
-
2018
- 2018-04-12 US US15/951,197 patent/US10211534B2/en active Active
- 2018-05-03 CY CY20181100459T patent/CY1120187T1/el unknown
- 2018-05-17 HR HRP20180773TT patent/HRP20180773T1/hr unknown
- 2018-10-16 AU AU2018250378A patent/AU2018250378B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508764A5 (ja) | ||
| JP2019147832A5 (ja) | ||
| Gazi et al. | Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins | |
| EP2528594B1 (en) | Effervescent formulations comprising second generation cephalosporin | |
| JP2013518056A5 (ja) | ||
| JP2020007356A5 (ja) | ||
| JP2011201907A5 (ja) | ||
| JP2017516848A5 (ja) | ||
| JP2016525572A5 (ja) | ||
| RU2012136147A (ru) | Антимикробные агенты и способы их применения | |
| WO2017174571A1 (en) | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease | |
| JP2017516847A5 (ja) | ||
| UY30357A1 (es) | Suspension acuosa estable | |
| SI3119201T1 (en) | Sildenafil solutions and procedures for their manufacture and use | |
| JP2020514282A5 (ja) | ||
| RU2012101816A (ru) | Композиции кандесартана цилексетила в форме наночастиц, способ их получения и содержащие их фармацевтические композиции | |
| JP2023537948A (ja) | コロナウイルス、インフルエンザ及び急性呼吸窮迫症候群を治療するための方法及び組成物 | |
| Shin et al. | Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate | |
| RU2012101817A (ru) | Композиции олмесартана медоксомила в форме наночастиц, способ их получения и содержащие их фармацевтические композиции | |
| EA201591435A1 (ru) | Новая композиция соединения ацетаминофена без побочного эффекта на печень | |
| JP2021119164A5 (ja) | ||
| JP2007500176A5 (ja) | ||
| JP2021102624A (ja) | Ｃｙｒ６１及びｖｅｇｆ媒介性の状態の治療 | |
| JP2020510619A5 (ja) | ||
| JP2015536995A5 (ja) |